Chemistry:PEAQX
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | PEAQX, NVP-AAM077 |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H17BrN3O5P |
| Molar mass | 454.217 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.[2]
References
- ↑ "Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission". Molecular Pharmacology 70 (3): 1022–32. September 2006. doi:10.1124/mol.106.024042. PMID 16778008.
- ↑ "5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition". Bioorganic & Medicinal Chemistry Letters 12 (7): 1099–102. April 2002. doi:10.1016/s0960-894x(02)00074-4. PMID 11909726.
 |  |
